SCHEMBL10256282

SCHEMBL10256282

CS(=O)(=O)Nc1cccc(-c2cnc3[nH]cc(C(=O)c4ccc5c(c4)OCCO5)c3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 8/20 0.49
MAP2K4 P45985 1/20 0.48
PIK3CA P42336 2/20 0.46
AAK1 Q2M2I8 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CAMKK2 Q96RR4 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
BTK Q06187 1/20 0.42
CLK1 P49759 1/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK2 Q92630 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
AXL P30530 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL413719 0.86 TNIK (0.47) TNIKPIK3CAAAK1CAMKK2CYP2C9
SCHEMBL857599 0.84 BRAF (0.54) TNIKPIK3CAAAK1CAMKK2CYP2C9
SCHEMBL878738 0.84 TNIK (0.55) TNIKPIK3CAAAK1CYP2C9CYP2C19
SCHEMBL3706659 0.83 INSR (0.55) TNIKPIK3CAAAK1CAMKK2CYP2C9
SCHEMBL298800 0.83 TNIK (0.54) TNIKPIK3CAAAK1CAMKK2CYP2C9
SCHEMBL878650 0.83 TNIK (0.54) TNIKPIK3CAAAK1SMN1; SMN2CAMKK2
SCHEMBL414867 0.82 TNIK (0.53) TNIKPIK3CAAAK1CYP2C9CYP2C19
SCHEMBL415724 0.82 TNIK (0.51) TNIKMAP2K4PIK3CARAB9ASMN1; SMN2
SCHEMBL859071 0.82 TNIK (0.49) TNIKPIK3CAAAK1SMN1; SMN2CAMKK2
SCHEMBL10256566 0.81 BRD4 (0.52) PIK3CAAAK1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053177-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-03-01 US disclosed
US-20120053177-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053177-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 TNIK 313/4885MAP2K4 224/4885PIK3CA 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.